Free tool
FAERS Monitor: Humulin 70/30 Pen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 019717 or its brand name (Humulin 70/30 Pen, Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human). Reports on generic versions are filed under their own applications.
Reports
16,106
Serious
10,597
66% of reports
Hospitalization
6,042
Death reported
1,307
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased3,691
- blood glucose decreased1,150
- drug ineffective1,038
- incorrect dose administered753
- hypoglycaemia689
- nausea641
- dyspnoea600
- weight decreased594
- visual impairment573
- diarrhoea552
- fall548
- dizziness505
- fatigue477
- malaise472
- vomiting462
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 503 |
| 2005 | 543 |
| 2006 | 765 |
| 2007 | 442 |
| 2008 | 314 |
| 2009 | 394 |
| 2010 | 348 |
| 2011 | 354 |
| 2012 | 351 |
| 2013 | 409 |
| 2014 | 686 |
| 2015 | 2,902 |
| 2016 | 616 |
| 2017 | 457 |
| 2018 | 745 |
| 2019 | 764 |
| 2020 | 744 |
| 2021 | 806 |
| 2022 | 956 |
| 2023 | 874 |
| 2024 | 866 |
| 2025 | 779 |
| 2026 | 488 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose decreasedSignal | 1,150 | 32.0 | 30.3 | 33,774 |
| blood glucose increasedSignal | 3,691 | 26.1 | 25.3 | 88,020 |
| hypoglycaemiaSignal | 689 | 18.8 | 17.5 | 11,458 |
| visual impairmentSignal | 573 | 6.1 | 5.6 | 2,420 |
| incorrect dose administeredSignal | 753 | 4.3 | 4.0 | 1,932 |
| weight decreasedSignal | 594 | 2.8 | 2.6 | 684 |
| fallSignal | 548 | 2.2 | 2.0 | 342 |
| malaise | 472 | 1.4 | 1.3 | 56 |
| dyspnoea | 600 | 1.4 | 1.3 | 65 |
| dizziness | 505 | 1.3 | 1.2 | 40 |
| vomiting | 462 | 1.3 | 1.2 | 29 |
| diarrhoea | 552 | 1.1 | 1.0 | 7 |
| nausea | 641 | 1.1 | 1.0 | 2 |
| drug ineffective | 1,038 | 1.0 | 1.0 | 1 |
| fatigue | 477 | 0.8 | 0.7 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.